- Study: Participation in diabetes education associated with greater ability to self-manage
- Study: Diabetes prevalence has doubled in past 25 years
- Tanzeum granted FDA approval
- Novo Nordisk launches new insulin device
- FDA advisory committees recommend approval of ultra rapid-acting mealtime insulin therapy
INDIANAPOLIS — Many people with Type 2 diabetes have managed to integrate the treatments they must take into their daily lives, but many do not reach their blood-glucose goals after they start insulin therapy.
Drug maker Eli Lilly is partnering with Brigham and Women's Hospital in Boston in a study that started in July and has enrolled 4,500 people in 17 countries to find out why many people with the disease resist a progression of insulin therapy.
Dubbed "MOSA1c," the study will gather data on insulin use, interactions between people who have and are treating diabetes and other factors involved in the progression of treatments.
"Fewer than half of people with diabetes reach their target goals for glycemic control, putting them at risk for complications like blindness, amputation, heart disease and kidney failure," Brigham and Women's Hospital physician, Harvard Medical School professor and study investigator William Shrank said. "The goal of this study is to determine the barriers that prevent patients from optimizing their insulin treatment, whether that is a lack of communication, health system hurdles or emotional responses."